Aims Hyoscine (scopolamine), which is effective in the prophylaxis of motion sickness, shows similar binding affinities to all of the five known muscarinic receptor sub-types. The effectiveness of hyoscine was compared with zamifenacin (UK-76654), which binds selectively to the muscarinic M 3 and m5 receptors. Methods Eighteen subjects received hyoscine hydrobromide 0.6 mg, zamifenacin 20 mg, or placebo (double-blind cross-over design). Sessions were 1 week apart and the drug (oral) was given 90 min prior to a motion sickness test. Motion sickness was elicited by cross-coupled stimulation on a turntable. The rotational velocity was incremented by 2°s −1 every 30 s, and a sequence (seq ) of eight head movements of 45°was completed every 30 s. Motion tolerance was assessed as the number of sequences of head movement required to achieve moderate nausea. Pulse rate was recorded before and at 1 and 2 h after drug administration. Skin conductance activity in the frequency band 0.005-0.48 Hz, an index of sweat gland activity, was measured using Ag/AgCl electrodes on the palmar surfaces of fingers and across the forehead.
Introduction Methods
The beneficial effect of hyoscine (scopolamine) in the Design prophylaxis of motion sickness is well established [1] . This drug shows similar binding affinities for all of the five known After a practice session without medication, each subject ingested hyoscine hydrobromide 0.6 mg, zamifenacin 20 mg, muscarinic receptor subtypes [2] . Zamifenacin (UK-76654), a selective muscarinic antagonist, has affinity for the M 3 or placebo according to a double-blind three period crossover design. Drugs were administered in the morning, muscarinic receptor subtype equivalent to that of atropine, while at the M 1 and M 2 receptors its affinity is less by followed at 90 min by the motion challenge. All sessions were at least 1 week apart. The dose of hyoscine factors of 50 and 100 respectively. The M 5 receptor has not been characterised pharmacologically, but studies using hydrobromide 0.6 mg is the standard single dose for antimotion sickness action. The choice of a 20 mg dose of cloned receptors (m1-m5) indicate that zamifenacin also shows a high affinity for the m5 receptor (Wallis, personal zamifenacin was determined on the basis that doses 2 to 3 times greater than this can produce side effects typical of communication).
We have compared the effectiveness of hyoscine and non-selective antimuscarinics (unpublished data on file). zamifenacin against motion sickness induced by crosscoupled motion. In addition the effects on heart rate, and on sweating measured by skin conductance, were Subjects investigated.
Subjects were eighteen healthy male volunteers aged between 19 and 46 years (mean age 28.7 s.d. 7.8 years) with intact vestibular function and not currently on other medications. The Motion Sickness Susceptibility Questionnaire (MSSQ) that the subject sample was only marginally more susceptible Heart rate than the general population. The subjects were fully briefed, gave informed consent in writing and were free to withdraw Pulse rate was measured at the wrist over a 1 min period, after sitting at rest for approx 5 min. The pulse rate was at any time. The study received ethical committee approval from the Ethics Committee of the RAF Institute of Aviation recorded immediately prior to drug ingestion, at 1 h postdrug and at 10 min following the cessation of the motion Medicine.
challenge (approximately 2 h post-drug).
Drug side-effects checklist Motion challenge
A checklist was administered immediately prior to drug Cross-coupled (Coriolis) motion was employed to elicit ingestion, at 1 h post-drug, and at 10 min after the cessation motion sickness [4] . Subjects were blindfolded and seated of the motion challenge (approximately 2 h post-drug ). The on a turntable equipped with slip-rings for power and data requested symptoms were: drowsiness, dry mouth, blurred lines. A staircase profile of (clockwise) rotational velocity vision, headache, nausea, abdominal pain, dizziness, sweating, was employed with increments from 2 to 120°s Statistical analysis symptoms however slight; 3=mild symptoms, eg, stomach awareness but no nausea; 4=mild nausea; 5=mild to Data were analysed by ANOVA for run order (order of the moderate nausea; 6=moderate nausea but can continue; treatment sessions), treatment (placebo, zamifenacin, hyos7=moderate nausea, wish to stop motion challenge [5] .
cine), and time to endpoint. ANOVAs revealed no run Following the cessation of the motion challenge, subjects order (session) effects on any variable and for brevity these remained seated and their recovery was recorded on the are not detailed below in results. Effects were further isolated 1-7 sickness rating scale every 0.5 min from 1 to 5 min.
by Newman-Keuls tests. Since some subjects on some In the first minute of recovery a motion sickness symptom treatment sessions reached the maximum cut-off time of checklist was administered for: dizziness, bodily warmth, 35 min, the data were treated as being right censored and headache, sweating, stomach awareness, increased salivation, maximum likelihood estimations were made for the right nausea, pallor, any other symptom(s). Symptoms were rated censored values with appropriate adjustments of degrees of as nil=0, mild=1, moderate=2, severe=3.
freedom. For the analysis of the SC data, a 2 min block of SC data was extracted from the beginning of the motion challenge, i.e. well prior to the onset of initial symptoms of motion sickness in all subjects, and a further block of SC Skin conductance data was taken over the 2 min preceding the endpoint of Skin conductance was recorded from 1st and 2nd finger the motion challenge, i.e. during the period of time of palmar sites of the non-dominant hand, and from the left maximum motion sickness. The differences between the and right sides of the forehead close to the hairline first and last 2 min blocks of each finger and head skin approximately 2 to 4 cm above the eyebrows [6] . Ag/AgCl conductance data set were addressed as a time factor in this electrodes were attached with double-sided self-adhesive analysis. The spectral powers for the first 96 frequencies of stickers (SLE Ltd). Total effective skin contact area was each block, representing the frequency band 0.005 to 0.32 cm 2 for each pair of electrodes. The electrolyte gel 0.480 Hz, were combined and log transformed to normalise used was 0.05m NaCl in low substitution methyl cellulose the variance of the data set. In addition, the 5 min period gel (BDH Ltd). The concentration of NaCl was in the following the cessation of the motion challenge, referred to range found in human sweat [7, 8] . Skin conductance was as the 'recovery phase', was analysed in 1 min blocks. measured using a constant current (10 mA) mains-isolated device. This device presented the output in two forms: the Results d.c.-coupled (tonic) skin conductance level (SCL) and the amplified 0.14 Hz high pass filtered ( phasic) skin conducTolerance to the motion challenge tance response (SCR). These signals were anti-alias filtered at 2Hz, digitised at a sampling rate of 5 Hz (A/D 12 bit ),
The number of sequences of head movements required to produce each sickness rating level is shown in Figure 1 . displayed on-line and stored on optical disc. The mean heart rate at 0 h (immediately prior to drug three treatments. Tolerance to the motion challenge was ingestion), 1 h and 2 h is plotted for the three treatment significantly greater following hyoscine (&, 0.6 mg) or conditions. The motion sickness challenge began at 1.5 h. The zamifenacin (f, 20 mg ), taken 90 min prior to the motion 2 h is an approximate time, being 10 min after the end of the challenge, as compared with placebo (%). Motion sickness was motion sickness challenge. Heart rate was significantly lower elicited by cross-coupled stimulation on a turntable. The following hyoscine ($, 0.6 mg) but not zamifenacin(%, 20 mg), rotational velocity was incremented by 2 deg.s the incidence of reponses increased in many of the categories irrespective of treatment condition. The only item to show a significant overall treatment effect was dry mouth (F= 4.8, df 2,24, P<0.05), where the mean scores for hyoscine Both zamifenacin and hyoscine treated subjects showed an increase in tolerance to the motion challenge compared and zamifenacin were both significantly higher than those for placebo (P<0.05). with placebo (P<0.01). Hyoscine treatment showed a difference from placebo of 5.7±1.6 seqs (mean±standard error of comparison), and zamifenacin a difference of Heart rate 5.0±1.6 seqs. Differences between zamifenacin and hyoscine at endpoint or at other sickness rating stages were non- Figure 2 presents the mean heart rate data. ANOVA showed a strong time effect ( F=33.2, df 2,24, P<0.001), a strong significant. ANOVA of sequences to each sickness rating showed no significant treatment effect at sickness rating=2, treatment effect (F=7.4, df 2,24, P<0.01) and significant treatment x time interaction (F=4.3, df 4,47, P<0.01). a marginal effect (F=2.9, df 2,23, P=0.05) at sickness rating=3, and significant treatment effects (P<0.01) at all
The source of the significant time effect was the significant fall in mean heart rate from pre-drug to 1 h post-drug higher sickness ratings.
(P<0.01), followed by a further significant drop in heart rate from 1 h to 2 h post-drug (P<0.001). The source of Recovery of sickness ratings after motion endpoint the significant treatment and treatment x time effects was that, whereas there were no significant differences between Sickness ratings reduced rapidly after cessation of motion; most subjects had recovered to the level of slight symptoms treatments pre-drug, at 1 h and 2 h post-drug lower mean heart rates (of the order of 9 beats min −1 overall) were by 5 min. There were no significant differences between treatments over all time points or at any particular time point.
observed with hyoscine compared with either placebo or zamifenacin ( P<0.01).
Symptom scores at motion endpoint Skin conductance Only sweating ( F=8.3, df 2,24, P<0.01) and bodily warmth (F=3.2, df 2,24, P=0.05 marginal) showed An example of skin conductance recording is shown in Figure 3 . Mean skin conductance activity is presented in treatment effects. With hyoscine, sweating scores were lower than those for placebo (P<0.01) or zamifenacin (P<0.05). Figure 4 , for the initial 2 min sample pre-motion sickness, and the final 2 min sample during motion sickness. The zamifenacin sweating score was lower than that for placebo but not significantly so. Bodily warmth scores were Forehead SC, expressed as mmho RMS in the frequency band 0.005-0.48 Hz, between the first and last 2 min of the lower for hyoscine than for placebo (P<0.05). All other comparisons were not significant. motion challenge increased overall from 0.006 to 0.023 (time effect: F=20.1, df 1,12, P<0.001). A significant treatment effect was observed (F=5.4, df 2,24, P<0.05) at Drug side-effects checklist the forehead recording site, and a significant treatment x time interaction (F=5.3, df 2,24, P<0.05). The source of The majority of positive responses were in the 'mild' category. At 2 h post-drug, i.e. after the motion challenge, these effects was that while at the beginning of the motion Sickness rating 0.05 µmho 0.05 µmho Figure 3 Example phasic skin conductance recordings at forehead and finger palmar recording sites from one subject during the motion challenge under placebo treatment. The simultaneously recorded sickness rating on the 1-7 scale is also shown. Note that, whereas the finger palmar site is active throughout reflecting nonspecific arousal responses to stimuli such as tape recorded instructions, the forehead site is quiescent until the onset of moderate nausea at around 12 min.
significant. The source of this effect was the reduction (P<0.001) of SC following hyoscine by an overall factor of 2.6±1.2. Although SC was reduced following zamifenacin, the change was not significant compared with that after placebo.
For the forehead recovery phase SC, significant effects were observed for time ( F=9.9, df 4,48, P<0.001), treatment ( F=5.5, df 2,24, P<0.05) , and time × treatment interaction ( F=3.4, df 8,96, P<0.01) . These effects were due to the significantly lower SC for hyoscine compared with placebo or zamifenacin ( P<0.05). The SC for placebo and zamifenacin had declined to that for hyoscine by the 5th min. For the finger recovery phase SC, a highly lower finger SC than that after placebo (P<0.05).
challenge there were no significant differences between
Other measures treatments, the SC at motion endpoint was lower following hyoscine than after either zamifenacin or placebo (0.0074 vs Vestibular-ocular, saccadic and Sternberg memory measures showed no significant treatment effects. Only the 0.37 Hz 0.025 or 0.028 mmho RMS, respectively, P<0.01).
Finger SC showed no significant time effect (first vs last visual pursuit gain showed a significant treatment effect (F=6.2, df 2,23, P<0.01). This was due to the lower 2 min of the motion challenge). The treatment effect for finger SC was highly significant (F=11.7, df 2,24, pursuit gain at this frequency with hyoscine as compared with placebo (P<0.05). P<0.001) and the treatment x time interaction was not reduced subjective sweating are consistent with the wellDiscussion known profile action of antimuscarinics on secretory glands. We conclude that compounds with selective M 3 and/or The primary aim of this study was to investigate whether zamifenacin (UK-76654), which binds selectively to the M 3 m5 antagonism possess activity against motion sickness. It is possible that antagonism at one or both of these receptors is and m5 receptors, was effective against motion sickness. At the dose used, zamifenacin demonstrated significant protecthe basis of the anti-motion sickness action of hyoscine. tive action against provocative motion, and the degree of protection was equivalent to that afforded by hyoscine.
Zamifenacin (UK-76654) was supplied by Pfizer UK Ltd.
